Check out our most popular compounded medications! Get Started
Morphine Sulfate 40 mg/mL Intravenous Infusion is a compounded medication designed for direct administration into the bloodstream via a sterile intravenous bag. This formulation provides precise and controlled relief for patients in end-of-life hospice care.
It is primarily used to manage severe pain and alleviate symptoms associated with terminal illnesses, including cancer, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF).
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 40 mg/mL Intravenous Infusion is a potent opioid analgesic formulation specifically designed for administration via an intravenous bag. This formulation is particularly utilized in end-of-life hospice care, where managing severe pain and providing comfort are paramount. The intravenous route allows for immediate delivery of the medication into the bloodstream, offering precise control over dosing and rapid onset of action, which is crucial for patients experiencing significant pain that requires swift relief.
In the context of hospice care, Morphine Sulfate is employed to alleviate severe pain and dyspnea, enhancing the quality of life for patients in their final stages. It works by binding to opioid receptors in the central nervous system, altering the perception of pain and emotional response to discomfort. This mechanism not only provides pain relief but also helps in reducing anxiety and distress associated with severe pain, contributing to a more peaceful and dignified end-of-life experience.
For prescribers, it is essential to consider the patient's overall condition, including renal and hepatic function, when determining the appropriate dosage of Morphine Sulfate. The 40 mg/mL concentration allows for flexibility in dosing, accommodating the varying needs of patients based on their pain levels and tolerance to opioids. Close monitoring is advised to adjust the dosage as needed and to manage any potential side effects, such as respiratory depression, sedation, or gastrointestinal disturbances.
Patients and caregivers should be informed about the potential side effects and the importance of adhering to the prescribed dosage regimen. It is crucial to communicate any changes in the patient's condition to the healthcare provider promptly. The use of Morphine Sulfate in hospice care is aimed at maximizing comfort and minimizing suffering, and it should be part of a comprehensive care plan that includes emotional and psychological support.
For any questions or further information regarding the use of Morphine Sulfate 40 mg/mL Intravenous Infusion in hospice care, please reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to assist you with any inquiries or concerns you may have.
Morphine Sulfate 40 mg/mL Intravenous Infusion is a potent opioid analgesic used primarily in end-of-life hospice care to manage severe pain and improve the quality of life for patients. Understanding these interactions is essential for both patients and prescribers to ensure optimal treatment outcomes.
One of the primary concerns with Morphine Sulfate is its interaction with other central nervous system (CNS) depressants. Concomitant use with benzodiazepines, barbiturates, or other opioids can lead to enhanced sedative effects, respiratory depression, profound sedation, coma, or even death. It is vital to monitor patients closely if these medications are used together, and dosage adjustments may be necessary to mitigate risks.
Additionally, morphine is metabolized by the liver enzyme CYP2D6. Drugs that inhibit this enzyme, such as certain antidepressants (e.g., fluoxetine, paroxetine) and antipsychotics, can lead to increased plasma concentrations of morphine, potentially enhancing its effects and side effects. Conversely, inducers of CYP2D6, like rifampin, may reduce morphine's effectiveness by increasing its metabolism, necessitating dosage adjustments.
Patients taking monoamine oxidase inhibitors (MAOIs) should avoid using morphine, as this combination can result in severe and unpredictable reactions, including serotonin syndrome, characterized by symptoms such as agitation, hallucinations, rapid heart rate, and increased body temperature. A minimum of 14 days should elapse between discontinuation of MAOIs and initiation of morphine therapy.
Furthermore, morphine can interact with anticholinergic drugs, potentially leading to increased risk of urinary retention and severe constipation. Patients should be monitored for these adverse effects, and appropriate measures should be taken to manage them if they occur.
It is also important to consider the interaction of morphine with diuretics. Morphine may reduce the efficacy of diuretics by inducing the release of antidiuretic hormone, leading to fluid retention. Monitoring fluid balance and adjusting diuretic therapy may be necessary in such cases.
Lastly, alcohol should be avoided while receiving morphine sulfate infusion, as it can potentiate the sedative and respiratory depressant effects of morphine, increasing the risk of serious adverse outcomes.
For any questions or concerns regarding the use of Morphine Sulfate 40 mg/mL Intravenous Infusion and its potential drug interactions, please reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to assist you in ensuring appropriate treatment for your patients.
Morphine Sulfate 40 mg/mL Intravenous Infusion is a potent opioid analgesic formulation specifically designed for use in end-of-life hospice care. This formulation is delivered through an intravenous bag, a sterile container that allows for the direct administration of the medication into the patient's bloodstream. This method of delivery ensures that the medication is rapidly absorbed and distributed throughout the body. The intravenous route is particularly beneficial in hospice care settings where patients may have difficulty swallowing or absorbing oral medications due to their condition.
The primary mechanism of action of morphine sulfate involves its interaction with the central nervous system. Morphine binds to and activates the mu-opioid receptors in the brain and spinal cord. This activation leads to the inhibition of pain signal transmission, altering the perception of pain and providing significant analgesic effects. Additionally, morphine can induce a sense of euphoria and relaxation, which can be particularly beneficial in alleviating the psychological distress often associated with end-of-life conditions.
In hospice care, the goal is to ensure the highest possible quality of life for patients by managing pain and other distressing symptoms. By providing consistent and controlled pain relief, this formulation helps to improve the patient's comfort and overall well-being. The precise dosing capability of the intravenous infusion allows healthcare providers to tailor the treatment to the individual needs of the patient, ensuring optimal pain management while minimizing potential side effects.
For prescribers, it is crucial to consider the patient's overall condition, including their renal and hepatic function, as these can affect morphine metabolism and excretion. Close monitoring is essential to adjust the dosage as needed and to manage any adverse effects, such as respiratory depression, which is a known risk with opioid use. The use of morphine sulfate in hospice care should always be part of a comprehensive palliative care plan, involving a multidisciplinary team to address all aspects of the patient's needs.
It is important to communicate openly with healthcare providers about any concerns or questions regarding the treatment plan. If you have any questions or need further information about this formulation, please reach out to us at Bayview Pharmacy. We are here to support you and ensure that you receive the best possible care.
Morphine sulfate 40 mg/mL intravenous infusion is primarily utilized for the management of severe pain, often associated with end-of-life hospice care. However, it has other potential applications that extend beyond this typical usage. This high-concentration intravenous formulation can be employed in acute settings where rapid onset of pain relief is crucial, such as in postoperative pain management or during severe trauma. Morphine sulfate's ability to modulate severe pain can significantly enhance patient comfort during complex medical procedures or in critical care units where pain control is crucial to patient outcomes and recovery processes.
In addition to its analgesic properties, morphine sulfate possesses vasodilatory effects that may be beneficial in cases of acute pulmonary edema. The reduction in preload and afterload can act as adjunct support in managing dyspnea and other symptoms, although this remains a secondary use and should be monitored carefully within a hospital setting. Morphine’s impact on the central nervous system can also be helpful in sedation protocols, where managing patient anxiety or agitation is essential, particularly when invasive procedures are anticipated.
While the primary indication for this high-dose formulation remains severe pain and palliative care scenarios, understanding its pharmacological versatility can expand its utility in various other medical conditions requiring immediate and effective intervention. Prescribers considering the use of morphine sulfate should thoroughly evaluate the patient’s medical history, potential drug interactions, and specific clinical needs to ensure the formulation's benefits outweigh the risks, as the potency of this concentration can significantly amplify side effects such as respiratory depression. Patients and healthcare providers should engage in open communication regarding treatment goals, anticipated side effects, and alternative pain management strategies to optimize therapeutic outcomes safely.
If you have any questions or require further information on how this formulation may be utilized in various clinical scenarios, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of expert compounding pharmacists is ready to provide personalized guidance tailored to meet the specific needs of both patients and healthcare providers.
```Morphine Sulfate 40 mg/mL Intravenous Infusion is a customized compounded medication administered directly into the bloodstream to provide pain relief and comfort for patients in end-of-life hospice care.
The medication is administered using an intravenous bag, which delivers the compound directly into the patient's bloodstream for immediate and controlled relief.
This formulation is used in hospice care to offer significant pain management for patients experiencing severe pain, ensuring comfort during end-of-life care.
Patients may experience side effects such as drowsiness, dizziness, nausea, or constipation. It’s important to monitor patients and communicate with healthcare providers about any adverse effects.
The medication is prepared by a licensed pharmacist who compounds the precise formulation to meet the specific needs of patients, ensuring safety and efficacy.
Safety is ensured through sterile compounding environments, precise dosing, and healthcare provider monitoring throughout the administration process.
Yes, the dosage can be tailored to the specific pain management needs of each patient, allowing for individualized care and comfort.
Because the medication is administered directly into the bloodstream, patients often experience pain relief almost immediately, which is critical in managing end-of-life pain.
Caregivers should be aware of the medication's purpose, potential side effects, and the importance of following healthcare provider instructions for administration and monitoring.
In end-of-life hospice care, the primary goal is to alleviate pain and provide comfort. Concerns about addiction are generally secondary due to the focus on quality of life.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
